{"drugbank-id":"BIOD00071","protein-name":"Low affinity immunoglobulin gamma Fc region receptor II-a","gene-symbol":"FCGR2A","rs-id":"rs1801274","uniprot-id":"P12318","allele":"","defining-change":"H allelle","description":"Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.","pubmed-id":"17704420"}
{"drugbank-id":"BIOD00071","protein-name":"Low affinity immunoglobulin gamma Fc region receptor III-A","gene-symbol":"FCGR3A","rs-id":"rs396991","uniprot-id":"P08637","allele":"","defining-change":"G \u003e T","description":"Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.","pubmed-id":"17704420"}
{"drugbank-id":"BIOD00043","protein-name":"Interferon lambda-3","gene-symbol":"IFNL3","rs-id":"rs12979860","uniprot-id":"Q8IZI9","allele":"","defining-change":"C \u003e T","description":"Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2a therapy.","pubmed-id":"24096968"}
{"drugbank-id":"BIOD00048","protein-name":"Interferon lambda-3","gene-symbol":"IFNL3","rs-id":"rs12979860","uniprot-id":"Q8IZI9","allele":"","defining-change":"C \u003e T","description":"Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2b therapy.","pubmed-id":"24096968"}
{"drugbank-id":"BIOD00004","protein-name":"Low affinity immunoglobulin gamma Fc region receptor III-A","gene-symbol":"FCGR3A","rs-id":"rs1801274","uniprot-id":"P08637","allele":"","defining-change":"CC Allele (homozygous)","description":"Patients with this genotype have increased ACR20 response when using infliximab to treat rheumatoid arthritis.","pubmed-id":"18930989"}
{"drugbank-id":"BIOD00014","protein-name":"Low affinity immunoglobulin gamma Fc region receptor III-A","gene-symbol":"FCGR3A","rs-id":"rs396991","uniprot-id":"P08637","allele":"FCGR3A","defining-change":"T \u003e G","description":"Patients with this genotype have increased frequency of anti-tumor response when using rituximab to treat diffuse large B-cell lymphoma, follicular lymphoma, or [follicular non-Hodgkin lymphoma].","pubmed-id":"16609067"}
{"drugbank-id":"APRD00328","protein-name":"Kinesin-like protein KIF6","gene-symbol":"KIF6","rs-id":"rs20455","uniprot-id":"Q6ZMV9","allele":"","defining-change":"C Allele","description":"Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin.","pubmed-id":"18222353"}
{"drugbank-id":"APRD00328","protein-name":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","gene-symbol":"HMGCR","rs-id":"rs17244841","uniprot-id":"P04035","allele":"","defining-change":"T Allele","description":"Patients with this genotype have a lesser reduction in LDL cholesterol with pravastatin.","pubmed-id":"15199031"}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":""}
{"drugbank-id":"APRD00425","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.","pubmed-id":""}
{"drugbank-id":"APRD00009","protein-name":"Angiotensin-converting enzyme","gene-symbol":"ACE","rs-id":"rs4344","uniprot-id":"P12821","allele":"","defining-change":"A Allele, homozygote","description":"Patients with this genotype have a shorter time to lowering of blood pressure with ramipril","pubmed-id":"17885551"}
{"drugbank-id":"APRD00556","protein-name":"Angiotensin-converting enzyme","gene-symbol":"ACE","rs-id":"rs1799752","uniprot-id":"P12821","allele":"","defining-change":"Alu insertions","description":"Patients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunction","pubmed-id":"12837457"}
{"drugbank-id":"APRD00556","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T allele, homozygote","description":"Patients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunction","pubmed-id":"12576843"}
{"drugbank-id":"APRD00147","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"C Allele","description":"Patients with this genotype have an increased likelihood of remission when using citalopram to treat major depressive disorder","pubmed-id":"17913323"}
{"drugbank-id":"APRD00147","protein-name":"5-hydroxytryptamine receptor 2A","gene-symbol":"HTR2A","rs-id":"rs7997012","uniprot-id":"P28223","allele":"","defining-change":"A Allele","description":"Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder","pubmed-id":"16642436"}
{"drugbank-id":"APRD00147","protein-name":"Glutamate receptor ionotropic, kainate 4","gene-symbol":"GRIK4","rs-id":"rs1954787","uniprot-id":"Q16099","allele":"","defining-change":"C Allele","description":"Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder","pubmed-id":"17671280"}
{"drugbank-id":"APRD00945","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to elitriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"APRD00241","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of phenytoin.","pubmed-id":"15805193"}
{"drugbank-id":"APRD00208","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801252","uniprot-id":"P08588","allele":"","defining-change":"A Allele","description":"Patients with this genotype have a greater reduction in blood pressure with metoprolol.","pubmed-id":"12844134"}
{"drugbank-id":"APRD00208","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"Patients with this genotype have reduced metabolism of metoprolol.","pubmed-id":"18784654"}
{"drugbank-id":"APRD00208","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801253","uniprot-id":"P08588","allele":"","defining-change":"G \u003e C","description":"Patients with this genotype have a greater reduction in blood pressure with metoprolol.","pubmed-id":"12844134"}
{"drugbank-id":"DB09359","protein-name":"Cytochrome P450 1A2","gene-symbol":"CYP1A2","rs-id":"","uniprot-id":"P05177","allele":"-2964(G/A)","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of theophylline.","pubmed-id":"12732846"}
{"drugbank-id":"APRD00125","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of venlafaxine.","pubmed-id":"16958828"}
{"drugbank-id":"APRD00125","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"T deletion","description":"Patients with this genotype have reduced metabolism of venlafaxine.","pubmed-id":"16958828"}
{"drugbank-id":"APRD00125","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole gene deletion, homozygote","description":"Patients with this genotype have reduced metabolism of venlafaxine.","pubmed-id":"16958828"}
{"drugbank-id":"APRD00125","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"C Allele","description":"Patients with this genotype have an increased likelihood of remission when using venlafaxine to treat major depressive disorder","pubmed-id":"17913323"}
{"drugbank-id":"APRD00125","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"T \u003e C","description":"Patients with this genotype have increased risk of adverse events with venlafaxine","pubmed-id":"22641028"}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":"25919121"}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele, homozygote","description":"The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":"25919121"}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole Gene Deletion","description":"The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":"25919121"}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"T deletion, homozygote","description":"The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":"25919121"}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":""}
{"drugbank-id":"APRD00614","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.","pubmed-id":""}
{"drugbank-id":"EXPT00718","protein-name":"Bleomycin hydrolase","gene-symbol":"BLMH","rs-id":"rs10500565","uniprot-id":"Q13867","allele":"","defining-change":"G Allele","description":"Patients with this genotype have reduced survival time and increased frequency of early relapse when using bleomycin to treat testicular cancer.","pubmed-id":"18398146"}
{"drugbank-id":"DB05354","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs1045642","uniprot-id":"P08183","allele":"","defining-change":"T Allele","description":"Patients with this genotype may have an increased analgesic response to morphine.","pubmed-id":"17898703"}
{"drugbank-id":"DB05354","protein-name":"Mu-type opioid receptor","gene-symbol":"OPRM1","rs-id":"rs1799971","uniprot-id":"P35372","allele":"","defining-change":"A Allele","description":"Patients with this genotype may have an increased analgesic response to morphine.","pubmed-id":"17898703"}
{"drugbank-id":"APRD00376","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to zolmitriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"DB07998","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121434568","uniprot-id":"P00533","allele":"L858R","defining-change":"T \u003e G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB07998","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs28929495","uniprot-id":"P00533","allele":"G719A/C","defining-change":"G \u003e A or C or T","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB07998","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121913444","uniprot-id":"P00533","allele":"L861Q","defining-change":"T \u003e A or G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of codeine.","pubmed-id":"1782973"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"T deletion, homozygote","description":"Patients with this genotype have reduced metabolism of codeine.","pubmed-id":"1782973"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole gene deletion, homozygote","description":"Patients with this genotype have reduced metabolism of codeine.","pubmed-id":"1782973"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced drug mtabolism or reduced therapeutic response when treated with codeine.","pubmed-id":"24458010"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.","pubmed-id":"24458010"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine and lack of therapeutic response from codeine.","pubmed-id":"24458010"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.","pubmed-id":"24458010"}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.","pubmed-id":""}
{"drugbank-id":"DB09471","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.","pubmed-id":""}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of amitriptyline.","pubmed-id":"18070221"}
{"drugbank-id":"APRD00227","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"C Allele","description":"Patients with this genotype have an increased likelihood of remission when using amitriptyline to treat major depressive disorder","pubmed-id":"17913323"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"G \u003e A","description":"Patients with this genotype have reduced metabolism of amitriptyline.","pubmed-id":"20531370"}
{"drugbank-id":"APRD00227","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"T \u003e C","description":"Patients with this genotype have increased risk of adverse events with amitriptyline","pubmed-id":"22641028"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":""}
{"drugbank-id":"APRD00227","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.","pubmed-id":""}
{"drugbank-id":"APRD00138","protein-name":"5-hydroxytryptamine receptor 1A","gene-symbol":"HTR1A","rs-id":"rs6295","uniprot-id":"P08908","allele":"","defining-change":"CC Allele (homozygous)","description":"The presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with olanzapine.","pubmed-id":"20533011"}
{"drugbank-id":"APRD00172","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801253","uniprot-id":"P08588","allele":"","defining-change":"G \u003e C","description":"Patients with this genotype have a greater reduction in blood pressure with atenolol.","pubmed-id":"22192668"}
{"drugbank-id":"APRD00446","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of omeprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00446","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of omeprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00473","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801253","uniprot-id":"P08588","allele":"","defining-change":"C \u003e G","description":"Patients with this genotype require a lower dosage of diltiazem to achieve a favourable rate-control response when treating atrial fibrillation.","pubmed-id":"22192668"}
{"drugbank-id":"APRD00520","protein-name":"Natriuretic peptides A","gene-symbol":"NPPA","rs-id":"rs5065","uniprot-id":"P01160","allele":"","defining-change":"AA allele","description":"Patients with this genotype have increased risk of adverse cardiovascular outcomes with diuretics.","pubmed-id":"18212314"}
{"drugbank-id":"APRD00077","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of lansoprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00077","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of lansoprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00077","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs1045642","uniprot-id":"P08183","allele":"","defining-change":"C Allele,  heterozygote","description":"Patients with this genotype have increased plasma concentration of lansoprazole.","pubmed-id":"17190370"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of imipramine.","pubmed-id":"18070221"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of imipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":""}
{"drugbank-id":"DB08002","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.","pubmed-id":""}
{"drugbank-id":"APRD00373","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of celecoxib.","pubmed-id":"12893985"}
{"drugbank-id":"APRD00655","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of dextromethorphan.","pubmed-id":"10513455"}
{"drugbank-id":"APRD00655","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"T deletion, homozygote","description":"Patients with this genotype have reduced metabolism of dextromethorphan.","pubmed-id":"10513455"}
{"drugbank-id":"APRD00951","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs28929495","uniprot-id":"P00533","allele":"G719A/C","defining-change":"G \u003e A or C or T","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.","pubmed-id":"15118073"}
{"drugbank-id":"APRD00951","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121913444","uniprot-id":"P00533","allele":"L861Q","defining-change":"T \u003e A or G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.","pubmed-id":"15118073"}
{"drugbank-id":"APRD00951","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121434568","uniprot-id":"P00533","allele":"L858R","defining-change":"T \u003e G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.","pubmed-id":"15118073"}
{"drugbank-id":"APRD00408","protein-name":"Cytochrome P450 3A4","gene-symbol":"CYP3A4","rs-id":"rs2740574","uniprot-id":"P08684","allele":"CYP3A4*1B","defining-change":"G Allelle","description":"Patients with this genotype have reduced metabolism of cyclophosphamide to its active form and reduced disease free survival time when using cyclophosphamide to treat node-positive breast cancer.","pubmed-id":"20459744"}
{"drugbank-id":"APRD00408","protein-name":"Cytochrome P450 2B6","gene-symbol":"CYP2B6","rs-id":"rs4802101","uniprot-id":"P20813","allele":"CYP2B6*1G","defining-change":"C Allelle","description":"Patients with this genotype have reduced metabolism of cyclophosphamide to its active form.","pubmed-id":"17502835"}
{"drugbank-id":"APRD00512","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of mephenytoin.","pubmed-id":"7969038"}
{"drugbank-id":"APRD00512","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs41291556","uniprot-id":"P33261","allele":"CYP2C19*8","defining-change":"T \u003e C","description":"Patients with this genotype have reduced metabolism of mephenytoin.","pubmed-id":"10411572"}
{"drugbank-id":"APRD00512","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs72558186","uniprot-id":"P33261","allele":"CYP2C19*7","defining-change":"T \u003e A","description":"Patients with this genotype have reduced metabolism of mephenytoin.","pubmed-id":"10411572"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of nortriptyline.","pubmed-id":"18070221"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":""}
{"drugbank-id":"APRD00602","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.","pubmed-id":""}
{"drugbank-id":"APRD00337","protein-name":"Sodium channel protein type 1 subunit alpha","gene-symbol":"SCN1A","rs-id":"rs3812718","uniprot-id":"P35498","allele":"","defining-change":"IVS5N + 5 G\u003eA","description":"Patients with this genotype have increased resistance to the anti-epileptic effects of carbamazepine.","pubmed-id":"24052718"}
{"drugbank-id":"APRD00543","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs12248560","uniprot-id":"P33261","allele":"CYPC19*17","defining-change":"C \u003e T","description":"Patients with this genotype in CYP2C19 are ultra fast metabolizers and require higer doses of voriconazole to attain the therapeutic effect.","pubmed-id":"27981572"}
{"drugbank-id":"APRD00543","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of voriconazole.","pubmed-id":"27981572"}
{"drugbank-id":"APRD00543","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of voriconazole.","pubmed-id":"27981572"}
{"drugbank-id":"DB07709","protein-name":"Cytochrome P450 2B6","gene-symbol":"CYP2B6","rs-id":"rs3745274","uniprot-id":"P20813","allele":"CYP2B6*6","defining-change":"G \u003e T","description":"The presence of this polymorphism in CYP2B6 is associated with reduction in efavirenz metabolism.","pubmed-id":""}
{"drugbank-id":"APRD00104","protein-name":"Kinesin-like protein KIF6","gene-symbol":"KIF6","rs-id":"rs20455","uniprot-id":"Q6ZMV9","allele":"","defining-change":"C Allele","description":"Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose simvastatin.","pubmed-id":"18222353"}
{"drugbank-id":"APRD00104","protein-name":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","gene-symbol":"HMGCR","rs-id":"rs17244841","uniprot-id":"P04035","allele":"","defining-change":"T Allele","description":"Patients with this genotype have a lesser reduction in LDL cholesterol with simvastatin.","pubmed-id":"15199031"}
{"drugbank-id":"APRD00335","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801253","uniprot-id":"P08588","allele":"","defining-change":"G \u003e C","description":"Patients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.","pubmed-id":"22192668"}
{"drugbank-id":"APRD00379","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to sumatriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"APRD00123","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of tamoxifen resulting in reduced plasma concentrations its active form endoxifen.","pubmed-id":"17115111"}
{"drugbank-id":"APRD00341","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1799853","uniprot-id":"P11712","allele":"CYP2C9*2","defining-change":"T Allele","description":"Patients with this genotype have reduced metabolism of warfarin.","pubmed-id":"15608560"}
{"drugbank-id":"APRD00341","protein-name":"Vitamin K epoxide reductase complex subunit 1","gene-symbol":"VKORC1","rs-id":"rs9923231","uniprot-id":"Q9BQB6","allele":"","defining-change":"-1639G\u003eA","description":"Patients with this genotype in VKORC1 are associated with reduced metabolism of warfarin and increased risk of serious bleeding thus require lower doses.","pubmed-id":"28198005"}
{"drugbank-id":"APRD00341","protein-name":"Phylloquinone omega-hydroxylase CYP4F2","gene-symbol":"CP4F2","rs-id":"rs2108622","uniprot-id":"P78329","allele":"","defining-change":"T Allele, homozygous","description":"Patients with this genotype in CP4F2 may require higer doses of warfarin to attain therapeutic anticoagulant activity.","pubmed-id":"28198005"}
{"drugbank-id":"APRD00341","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1799853","uniprot-id":"P11712","allele":"CYP2C9*2","defining-change":"T Allele","description":"The presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.","pubmed-id":"28198005"}
{"drugbank-id":"APRD00341","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"The presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.","pubmed-id":"28198005"}
{"drugbank-id":"DB05067","protein-name":"Mu-type opioid receptor","gene-symbol":"OPRM1","rs-id":"rs1799971","uniprot-id":"P35372","allele":"","defining-change":"A \u003e G","description":"Patients with this genotype have an increased number of abstinent days when using naltrexone to treat alcohol addiction.","pubmed-id":"18250251"}
{"drugbank-id":"DB00715","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs2032583","uniprot-id":"P08183","allele":"","defining-change":"C Allele","description":"Patients with this genotype have an increased likelihood of remission when using paroxetine to treat major depressive disorder.","pubmed-id":"17913323"}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":"25974703"}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":"25974703"}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":"25974703"}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":"25974703"}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":""}
{"drugbank-id":"DB00715","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.","pubmed-id":""}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of trimipramine.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":""}
{"drugbank-id":"APRD00498","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.","pubmed-id":""}
{"drugbank-id":"APRD00363","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of esomeprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00363","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of esomeprazole.","pubmed-id":"9867757"}
{"drugbank-id":"APRD00534","protein-name":"Catechol O-methyltransferase","gene-symbol":"COMT","rs-id":"rs4680","uniprot-id":"P21964","allele":"","defining-change":"AA allele","description":"Patients with this genotype have reduced improvement in vigor and well-being with modafinil.","pubmed-id":"19037200"}
{"drugbank-id":"APRD00534","protein-name":"Catechol O-methyltransferase","gene-symbol":"COMT","rs-id":"rs4680","uniprot-id":"P21964","allele":"","defining-change":"GG allele","description":"Patients with this genotype have increased improvement in vigor and well-being with modafinil.","pubmed-id":"19037200"}
{"drugbank-id":"APRD00444","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.","pubmed-id":"17900275"}
{"drugbank-id":"APRD00444","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"G \u003e A","description":"Patients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.","pubmed-id":"8195181"}
{"drugbank-id":"APRD00444","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clopidogrel.","pubmed-id":"23698643"}
{"drugbank-id":"APRD00579","protein-name":"Solute carrier organic anion transporter family member 1B1","gene-symbol":"SLCO1B1","rs-id":"rs4149056","uniprot-id":"Q9Y6L6","allele":"SLCO1B1*15","defining-change":"C Allele","description":"Patients with this genotype have reduced transport of the active metabolite of irinotecan resulting in increased plasma concentrations.","pubmed-id":"17898662"}
{"drugbank-id":"DB01693","protein-name":"Interferon lambda-3","gene-symbol":"IFNL3","rs-id":"rs12979860","uniprot-id":"Q8IZI9","allele":"","defining-change":"C \u003e T","description":"Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to ribavirin therapy.","pubmed-id":"24096968"}
{"drugbank-id":"APRD00039","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1080985","uniprot-id":"P10635","allele":"CYP2D6*2A","defining-change":"C \u003e G","description":"Patients with this genotype are have a decreased likelihood of responding to donepezil when treating Alzheimer's disease.","pubmed-id":"22465999"}
{"drugbank-id":"EXPT01437","protein-name":"Cytochrome P450 3A5","gene-symbol":"CYP3A5","rs-id":"","uniprot-id":"P20815","allele":"CYP3A5*1","defining-change":"Functional gene","description":"Patients with this genotype in CYP3A5 are extensive metabolizers and require higer doses of tacrolimus to attain the therapeutic effect.","pubmed-id":"25801146"}
{"drugbank-id":"APRD00481","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*1xN,","defining-change":"Gene duplication.","description":"Patients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.","pubmed-id":"28002639"}
{"drugbank-id":"APRD00481","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*2xN","defining-change":"Gene duplication.","description":"Patients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.","pubmed-id":"28002639"}
{"drugbank-id":"APRD00169","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to almotriptan when treating cluster headache.","pubmed-id":"17361120"}
{"drugbank-id":"EXPT00475","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of acetylsalicylic acid.","pubmed-id":"12893985"}
{"drugbank-id":"EXPT00475","protein-name":"Integrin beta-3","gene-symbol":"ITGB3","rs-id":"rs5918","uniprot-id":"P05106","allele":"GPIIIa PlA2","defining-change":"T \u003e C","description":"Patients with this genotype have increased resistance to the anti-thrombotic effects of aspirin.","pubmed-id":"11723016"}
{"drugbank-id":"APRD00220","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to naratriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"APRD00008","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to rizatriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"APRD00270","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"T Allele","description":"Patients with this genotype have an increased likelihood of responding to frovatriptan when treating (condition: cluster headache).","pubmed-id":"17361120"}
{"drugbank-id":"APRD00436","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of glipizide.","pubmed-id":"10208645"}
{"drugbank-id":"APRD00055","protein-name":"Kinesin-like protein KIF6","gene-symbol":"KIF6","rs-id":"rs20455","uniprot-id":"Q6ZMV9","allele":"","defining-change":"C Allele","description":"Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose atorvastatin.","pubmed-id":"18222353"}
{"drugbank-id":"APRD00055","protein-name":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","gene-symbol":"HMGCR","rs-id":"rs17244841","uniprot-id":"P04035","allele":"","defining-change":"T Allele","description":"Patients with this genotype have a lesser reduction in LDL cholesterol with atorvastatin.","pubmed-id":"15199031"}
{"drugbank-id":"APRD00055","protein-name":"Cytochrome P450 3A4","gene-symbol":"CYP3A4","rs-id":"rs2740574","uniprot-id":"P08684","allele":"CYP3A4*1B","defining-change":"A \u003e G","description":"Patients with this genotype have an greater reduction in LDL cholesterol with atorvastatin.","pubmed-id":"22120734"}
{"drugbank-id":"APRD00546","protein-name":"Kinesin-like protein KIF6","gene-symbol":"KIF6","rs-id":"rs20455","uniprot-id":"Q6ZMV9","allele":"","defining-change":"C Allele","description":"Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose rosuvastatin.","pubmed-id":"18222353"}
{"drugbank-id":"APRD00546","protein-name":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","gene-symbol":"HMGCR","rs-id":"rs17244841","uniprot-id":"P04035","allele":"","defining-change":"T Allele","description":"Patients with this genotype have a lesser reduction in LDL cholesterol with rosuvastatin.","pubmed-id":"15199031"}
{"drugbank-id":"APRD00546","protein-name":"ATP-binding cassette sub-family G member 2","gene-symbol":"ABCG2","rs-id":"rs2231142","uniprot-id":"Q9UNQ0","allele":"","defining-change":"G \u003e T","description":"Patients with this genotype have a greater reduction in LDL cholesterol with rosuvastatin.","pubmed-id":"20130569"}
{"drugbank-id":"DB08567","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of sertraline.","pubmed-id":"25974703"}
{"drugbank-id":"DB08567","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of sertraline.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00456","protein-name":"Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3","gene-symbol":"GNB3","rs-id":"rs5443","uniprot-id":"P16520","allele":"","defining-change":"C \u003e T","description":"Patients with this genotype will lose weight with sibutramine.","pubmed-id":"19687782"}
{"drugbank-id":"APRD00460","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduction in gliclazide metabolism.","pubmed-id":"17298483"}
{"drugbank-id":"APRD00460","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduction in gliclazide metabolism.","pubmed-id":"17298483"}
{"drugbank-id":"APRD00267","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this genotype have reduced metabolism of tolbutamide.","pubmed-id":"8873220"}
{"drugbank-id":"APRD00188","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of proguanil.","pubmed-id":"13680037"}
{"drugbank-id":"APRD00188","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"A Allele, homozygote","description":"Patients with this genotype have reduced metabolism of proguanil.","pubmed-id":"13680037"}
{"drugbank-id":"APRD00091","protein-name":"Beta-1 adrenergic receptor","gene-symbol":"ADRB1","rs-id":"rs1801253","uniprot-id":"P08588","allele":"","defining-change":"C Allele, homozygous","description":"Patients with this genotype in ADRB1 have an increased likelihood of responding to carvedilol for the treatment of increased blood pressure.","pubmed-id":"12844134"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of doxepin.","pubmed-id":"27997040"}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":""}
{"drugbank-id":"APRD00398","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.","pubmed-id":""}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of desipramine.","pubmed-id":"18070221"}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":""}
{"drugbank-id":"DB07682","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.","pubmed-id":""}
{"drugbank-id":"APRD00621","protein-name":"D(2) dopamine receptor","gene-symbol":"DRD2","rs-id":"rs1800497","uniprot-id":"P14416","allele":"","defining-change":"C Allele, homozygous","description":"The presence of this genotype in DRD2 is associated with improved therapeutic response to bupropion.","pubmed-id":"18058343"}
{"drugbank-id":"APRD00683","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of escitalopram.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00683","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of escitalopram.","pubmed-id":"25974703"}
{"drugbank-id":"APRD00442","protein-name":"T-box transcription factor TBX21","gene-symbol":"TBX21","rs-id":"rs2240017","uniprot-id":"Q9UL17","allele":"","defining-change":"CG allele (heterozygotes)","description":"The presence of this polymorphism in TBX21 may be associated with improved responsiveness to budenoside for the treatment of asthma.","pubmed-id":"15604153"}
{"drugbank-id":"APRD00665","protein-name":"Potassium voltage-gated channel subfamily H member 2","gene-symbol":"KCNH2","rs-id":"rs1805123","uniprot-id":"Q12809","allele":"","defining-change":"A \u003e C","description":"The presence of this polymorphism in KCNH2 may be associated with increased clinical efficacy with metoclopramide.","pubmed-id":"22688145"}
{"drugbank-id":"APRD00665","protein-name":"Alpha-1D adrenergic receptor","gene-symbol":"ADRA1D","rs-id":"rs2236554","uniprot-id":"P25100","allele":"","defining-change":"A \u003e T","description":"The presence of this polymorphism in ADRA1D may be associated with increased clinical efficacy with metoclopramide.","pubmed-id":"22688145"}
{"drugbank-id":"APRD00665","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"G \u003e A","description":"Patients with this genotype have reduced metabolism of metoclopramide.","pubmed-id":"22688145"}
{"drugbank-id":"APRD00665","protein-name":"Multidrug resistance protein 1","gene-symbol":"ABCB1","rs-id":"rs1045642","uniprot-id":"P08183","allele":"","defining-change":"T Allele","description":"Patients with this polymorphism in ABCB1 may have a reduced response to clomipramine.","pubmed-id":"21840870"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A Allele","description":"Patients with this genotype have reduced metabolism of clomipramine.","pubmed-id":"18070221"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs35742686","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"2549delA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs3892097","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"A allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"","uniprot-id":"P10635","allele":"CYP2D6*5","defining-change":"Whole-gene deletion","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs5030655","uniprot-id":"P10635","allele":"CYP2D6*6","defining-change":"1707delT","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4244285","uniprot-id":"P33261","allele":"CYP2C19*2","defining-change":"681G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2C19","gene-symbol":"CYP2C19","rs-id":"rs4986893","uniprot-id":"P33261","allele":"CYP2C19*3","defining-change":"636G\u003eA","description":"The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":"27997040"}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs1135824","uniprot-id":"P10635","allele":"CYP2D6*3","defining-change":"G allele","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":""}
{"drugbank-id":"DB07600","protein-name":"Cytochrome P450 2D6","gene-symbol":"CYP2D6","rs-id":"rs28371733","uniprot-id":"P10635","allele":"CYP2D6*4","defining-change":"3877G\u003eA","description":"The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.","pubmed-id":""}
{"drugbank-id":"DB01418","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1799853","uniprot-id":"P11712","allele":"CYP2C9*2","defining-change":"T Allele","description":"The presence of this polymorphism in CYP2C9 is associated with reduction in acenocoumarol metabolism.","pubmed-id":"18021343"}
{"drugbank-id":"DB01418","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"The presence of this polymorphism in CYP2C9 is associated with reduction in acenocoumarol metabolism.","pubmed-id":"18021343"}
{"drugbank-id":"DB01418","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1799853","uniprot-id":"P11712","allele":"CYP2C9*2","defining-change":"T Allele","description":"Patients with this polymorphism in CYP2C9 may be at a higher risk of developing drug-related hemorrhage or thrombosis when treated with acenocoumarol.","pubmed-id":"28033245"}
{"drugbank-id":"DB01418","protein-name":"Cytochrome P450 2C9","gene-symbol":"CYP2C9","rs-id":"rs1057910","uniprot-id":"P11712","allele":"CYP2C9*3","defining-change":"C Allele","description":"Patients with this polymorphism in CYP2C9 may be at a higher risk of developing drug-related hemorrhage or thrombosis when treated with acenocoumarol.","pubmed-id":"28033245"}
{"drugbank-id":"DB05989","protein-name":"Cystic fibrosis transmembrane conductance regulator","gene-symbol":"CFTR","rs-id":"rs75527207","uniprot-id":"P13569","allele":"","defining-change":"A allele (G \u003e A), double homozygote","description":"Patients who carry this polymorphism in CFTR will respond to ivacaftor therapy.","pubmed-id":"23757359"}
{"drugbank-id":"DB08916","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121913444","uniprot-id":"P00533","allele":"L861Q","defining-change":"T \u003e A or G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB08916","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs121434568","uniprot-id":"P00533","allele":"L858R","defining-change":"T \u003e G","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB08916","protein-name":"Epidermal growth factor receptor","gene-symbol":"EGFR","rs-id":"rs28929495","uniprot-id":"P00533","allele":"G719A/C","defining-change":"G \u003e A or C or T","description":"The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.","pubmed-id":"15118073"}
{"drugbank-id":"DB08922","protein-name":"5-hydroxytryptamine receptor 1A","gene-symbol":"HTR1A","rs-id":"rs6295","uniprot-id":"P08908","allele":"","defining-change":"CC Allele (homozygous)","description":"The presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with perospirone.","pubmed-id":"20533011"}
{"drugbank-id":"DB08930","protein-name":"UDP-glucuronosyltransferase 1-1","gene-symbol":"UGT1A1","rs-id":"rs8175347","uniprot-id":"P22309","allele":"UGT1A1*28 or UGT1A 7/7","defining-change":"extra TA in promoter","description":"Poor drug metabolizer.","pubmed-id":"24329186"}
{"drugbank-id":"DB08930","protein-name":"UDP-glucuronosyltransferase 1-1","gene-symbol":"UGT1A1","rs-id":"rs4148323","uniprot-id":"P22309","allele":"UGT1A1*6","defining-change":"G \u003e A","description":"The presence of this polymorphism in UGT1A1 is associated with reduction in dolutegravir metabolism.","pubmed-id":"24329186"}
{"drugbank-id":"DB08930","protein-name":"UDP-glucuronosyltransferase 1-1","gene-symbol":"UGT1A1","rs-id":"rs8175347","uniprot-id":"P22309","allele":"UGT1A1*37","defining-change":"TA pair insertion","description":"The presence of this polymorphism in UGT1A1 is associated with reduction in dolutegravir metabolism.","pubmed-id":"24329186"}